Trial Profile
A retrospective study evaluating effectiveness and safety of Antihemophilic Factor (Recombinant), PEGylated for prophylaxis in patients with severe haemophilia A: a real world study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Dec 2018
Price :
$35
*
At a glance
- Drugs Rurioctocog alfa pegol (Primary)
- Indications Haemophilia A
- Focus Adverse reactions; Therapeutic Use
- 07 Dec 2018 New trial record